Abbott Laboratories (NYSE:ABT) will release earnings for the fourth quarter before the opening bell on Thursday, Jan. 22.
Analysts expect the Abbott Park, Illinois-based company to report fourth-quarter earnings of $1.49 per share. That’s up from $1.34 per share in the year-ago period. The consensus estimate for Abbott’s quarterly revenue is $11.8 billion (it reported $10.97 billion last year), according to Benzinga Pro.
On Jan. 20, Abbott received CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms.
Shares of Abbott fell 0.3% to close at $120.73 on Wednesday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- Bernstein analyst Lee Hambright maintained an Outperform rating and raised the price target from $150 to $154 on Jan. 9, 2026. This analyst has an accuracy rate of 60%.
- Barclays analyst Matt Miksic maintained an Overweight rating and boosted the price target from $162 to $169 on Jan. 5, 2026. This analyst has an accuracy rate of 65%.
- BTIG analyst Marie Thibault maintained a Buy rating and a price target of $145 on Nov. 20, 2025. This analyst has an accuracy rate of 60%.
- Raymond James analyst Jayson Bedford maintained an Outperform rating and raised the price target from $141 to $146 on Oct. 16, 2025. This analyst has an accuracy rate of 66%.
- Evercore ISI Group analyst Vijay Kumar maintained an Outperform rating and cut the price target from $144 to $142 on Oct. 16, 2025. This analyst has an accuracy rate of 60%
Considering buying ABT stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments